Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	CRC, Ovarian & Endometrial	IV	D3-002 A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours	Dr Matthew Ng	NCT02521844	Open
2	Epithelial sarcoma, NPC, Gastric, Prostate Ovarian & DLBCL	IV	CMAK683X2101 A Phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies	Dr Daniel Tan	NCT02900651	On hold
3	NSCLC, Melanoma, all solid tumors except CRC	IV	CTNO155X2101 An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors	Dr Daniel Tan	NCT03114319	Open
4	CRC and PDAC	Advanced	CTMT212XSG01T Phase Ib study evaluating safety and tolerability of combination trametinib and ruxolitinib in patients with advanced RAS mutant colorectal cancer and pancreatic adenocarcinoma	Dr David Tai	NCT04303403	Open
5	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	CPDR001C2101 Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients	Dr Daniel Tan	NCT03064854	Open
6	All Solid Tumour	documented RET infusion	LOXO-RET-17001 A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity	Dr Daniel Tan	NCT03157128	Open
7	NSCLC, Pancreas and all solid tumors	IV	MCLA-128-CL01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors	Dr Justina Lam	NCT02912949	Open
8	All Solid Tumour with documented NTRK fusions	must had prior TRK inhibitor	LOXO-EXT-17005 A Phase 1/2 study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK fusion cancers	Dr Daniel Tan	NCT03215511	Open
9	NSCLC, TNBC, PDAC, RCC, Ovarian, CRC, Prostate	IV	CNZV930X2101 A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies	Dr Koo Si-Lin	NCT03549000	Open
10	NSCLC	with documented EGFR Exon 20 insertion mutation	CLN-081-001 A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	Dr Daniel Tan	NCT04036682	Open
11	Prostate	Advanced recurrent	Amgen 20180101 A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer	Dr Daniel Tan	NCT03792841	On hold
12	All Solid Tumour	documented RET infusion	LIBRETTO-201 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation	Dr Daniel Tan	NCT03906331	Open
13	All Solid Tumour	Advanced recurrent	THOR-707-101 An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors	Dr Tira Tan	NCT04009681	Open
14	Ovarian	Recurrent	ORION-02 / NCC OV-03 / CA209-7WC A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients with Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02)	Dr Jack Chan	NCT04620954	Open
15	All Solid Tumour	Advanced recurrent	TAPISTRY Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial	Dr Tira Tan	NCT04589845	Open
16	NSCLC, CRC	Advanced recurrent	CJDQ443A12101 A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation	Dr Daniel Tan	NCT04699188	Open
17	NSCLC	Advanced recurrent	DESTINY-Lung03 A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)	Dr Stephanie Saw	NCT04686305	Open
18	NSCLC	Advanced recurrent	Bayer 21607 An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation	Dr Daniel Tan	NCT05099172	Open
19	NSCLC	Advanced recurrent	BLU-945-1101 A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer	Dr Daniel Tan	NCT04862780	Open
20	Gastric	Metastatic gastric cancer with peritoneal mets	PIANO (CA209-7HC) Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin and in combination with Nivolumab in patients with peritoneal carcinomatosis	Dr Claramae Chia	NCT03172416	Open
21	ccRCC and HCC	Advanced recurrent	SRF388-101 A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors	Dr Toh Han Chong	NCT04374877	Open
22	Cholangio and all soild tumors	with FGFR2 mutation	RLY-4008-101 A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors Cancers	Dr David Tai	NCT04526106	Open
23	NSCLC HNSCC Urothelial	Advanced recurrent	BAYER 21343 An open-label, Phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors	Dr Daniel Tan	NCT04999202	On hold
24	All Solid Tumour	Advanced recurrent	ADG116-1003 A Phase 1, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined with ADG106 (Anti-CD137 Antibody), ADG116 Combined with Toripalimab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors	Dr Matthew Ng	NCT04501276	Open
25	Breast and Gastric	with HER2+	GO40311 A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS	Dr Tira Tan	NCT03448042	Open

Current clinical trials by body parts

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Bladder	Unresectable or Metastatic Urothelial Cancer	CA209-901 A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer	Dr Ravindran Kanesvaran	NCT03036098	Open
2	Bladder	Neoadjuvant and adjuvant chemotherpay for non-muscle invasive bladder cancer	CA017-078 A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer	Dr Ravindran Kanesvaran	NCT03661320	Open
3	Bladder	locally advanced or metastatic urothelial cancer	SGN22E-003/EV-302 An open- label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer	Dr Ravindran Kanesvaran	NCT04223856	Open
4	Breast	Metastatic	BEXMET Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype	Dr Elaine Lim	NCT04664829	Open
5	Breast	PIK3 CA-Mutant HR+, HER2 - LABC/MBC	WO41554 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC 0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant In Patients with Locally Advanced or Metastatic Pik3ca-Mutant Hormone Receptor-Positive, Her2 Negative Breast Cancer	Dr Yap Yoon Sim	NCT04191499	Open
6	Breast	Adjuvant / Metastatic	TCF20-BRE-01 An open-label, single-institution, dose-determining (Part I) and dose-confirmatory (Part II) study to investigate the optimal dose of Tamoxifen in breast cancer patients harboring different TCF20 rs932376 variant alleles	Dr Elaine Lim	NCT04961632	Open
7	Breast	TNBC	WO39391-IMPASSION 030 A Phase III, Multicenter, Randomized, Open-label Study Comparing ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) In Combination With Standard Adjuvant ANTHRACYCLINE/TAXANE-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable TRIPLE-NEGATIVE Breast Cancer	Dr Rebecca Dent	NCT03498716	Open
8	Breast	HER2+ Adj	WO42633-Astefania: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Atezolizumab or Placebo in Combination with Trastuzumab Emtansine as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer At Risk of Recurrence Who have Residual Tumor Present Pathologically in the Breast and/or Axillary Lymph Nodes Following Preoperative Therapy	Dr Yap Yoon Sim	NCT04873362	Open
9	Breast	HER2 +	DESTINY-Breast05: A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy	Dr Tira Tan	NCT04622319	Open
10	Breast	Mets TNBC	D9670C00001: DESTINY-Breast06: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting	Dr Rebecca Dent	NCT04494425	Open
11	Breast	Mets TNBC	MO39193-IMPASSION 132: Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Atezolizumab in Combination with Chemotherapy for Patients with Early Relapsing Recurrent (Inoperable Locally Advanced or Metastatic) Triple-Negative Breast Cancer	Dr Rebecca Dent	NCT03371017	Open
12	Colorectal	Neoadjuvant	OTSP-WoOCRC / MK-3475-886 Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer	Dr Iain Tan	NCT03984578	Open
13	Colorectal	Advance 2nd line	Mirati 849-010/KRYSTAL-10 A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy	Dr Dawn Chong	NCT04793958	Open
14	Esophageal	Unresectable Locally Advanced, Unresectable Recurrent, Metastatic, 1st line	YO42138 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Tiragolumab In Combination With Paclitaxel And Cisplatin Compared With Paclitaxel And Cisplatin As First-Line Treatment In Patients With Unresectable Locally Advanced, Unresectable Recurrent, Or Metastatic Esophageal Squamous Cell Carcinoma	Dr Matthew Ng	NCT04540211	Open
15	Gastric GEJ	Advanced 2nd line	DS8201-A-U306 A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen	Dr Matthew Ng	NCT04704934	Open
16	Gastric GEJ	Advanced 2nd and 3rd line	ASPEN-06 A Phase 2/3 Study of ALX148 In Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma	Dr Matthew Ng	NCT05002127	Open
17	Liver	Advance/ Metastatic 2nd line	CA224-073 A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors	Dr David Tai	NCT04567615	Open
18	Liver	Neoadjuvant + adjuvant	NCCS-OTSP-HCC1 / MK-3475-750 Longitudinal Immune-phenotyping of Surgically Resected HCC following Neoadjuvant and Adjuvant Treatment with MK – 3475	Dr Toh Han Chong	NCT04224480	Open
19	Liver	Adv 1st line	JS001-027-III-HCC A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)	Dr Joycelyn Lee	NCT04523493	Open
20	Liver	Adjuvant	CA209-7R9 An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)	Dr Koo Si Lin	NCT04912765	Open
21	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	BO29554 A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Dr Daniel Tan	NCT03178552	Open
22	Lung	LOCALLY ADVANCED/ METASTATIC - 2nd Line	MS200095-0031 A Phase II single arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy (INSIGHT2)	Dr Daniel Tan	NCT03940703	Open
23	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	TAK-788-3001 A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Dr Tanujaa	NCT04129502	Open
24	Lung	locally advanced or metastatic, 1st line	ATORG-0003 A Single-arm, Open-label, Phase 2 Study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation	Dr Daniel Tan	NCT04027647	Open
25	Lung	Adjuvant stage II-III	MeRmaiD-1 A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC	Dr Daniel Tan	NCT04385368	Open
26	Lung	Adjuvant stage II-III	MERMAID-2 A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy	Dr Daniel Tan	NCT04642469	Open
27	Lung	LA NSCLC	CA209-73L A Phase 3, Randomized, Open-Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)	Dr Daniel Tan	NCT04026412	Open
28	Lung	Mets NSCLC	LIBRETTO-431 - J2G-MC-JZJC A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer	Dr Daniel Tan	NCT04194944	Open
29	Lung	Mets NSCLC	TROPION-LUNG01 / DS1062-A-U301 Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations	Dr Amit Jain	NCT04656652	Open
30	Lung	Mest NSCLC	KRYSTAL-12 A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation	Dr Ang Mei Kim	NCT04685135	Open
31	Lymphoma	Relapsed/Refractory DLBCL	A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma	Dr Miriam Tao	NCT04628494	Open
32	Lymphoma	Relapsed/Refractory EBV+ Lymphomas	VT3996-202 An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)	Dr Nagavalli Somsundaram	NCT05011058	Open
33	Nasopharyngeal	Neoadjuvant / Stage IVA	NEO-SPACE Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer	Dr Darren Lim	NCT03734809	Open
34	Nasopharyngeal	Metastatic or recurrent nasopharyngeal carcinoma No more than 1 line	CA209-796 A phase II trial of Ipililumab in combination with nivolumab in patients with advanced nasopharyngeal carcinoma	Dr Darren Lim	NCT03097939	Open
35	Head and Neck	ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA First Line	ASPEN03 - AT148003 A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA	Dr Ang Mei Kim	NCT04675294	Open
36	Head and Neck	ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA First Line	ASPEN04 - AT148004 A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA	Dr Ang Mei Kim	NCT04675333	Open
37	Ovarian	Advanced	EPIK-O: CBYL719K1230 A Phase III, multi-center, randomized, open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer.	Dr Chay Wen Yee	NCT04729387	Open
38	Prostate	Metastatic	CA209-7Dx A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)	Dr Ng Quan Sing	NCT04100018	Open
39	Prostate	Metastatic	XL184-315 (CONTACT-02) A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer	Dr Ng Quan Sing	NCT04446117	Open
40	Prostate	Metastatic	Bayer 20510: A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH	Dr Ng Quan Sing	NCT04597125	Open
41	Sarcoma	Recurrent	Radical resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of high risk recurrent retroperitoneal sarcoma	Dr Johnny Ong	NCT03792867	Open

General

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	CLDK378A2X01B An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib	Dr Daniel Tan	NCT02584933	Open
2	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	LOXO-TRK-15002 (NAVIGATE) A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors	Dr Daniel Tan	NCT02576431	Open
3	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	APL10101 Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Dr Gillianne Lai	NCT03175224	Open
4	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	TPX-0005-01 A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)	Dr Darren Lim	NCT03093116	Open
5	SOLID TUMORS (currently only HCC and gastric cohorts are opened)	Advanced curatively unresectable solid tumors failing standard therapy. HCC: must have failed at least 1 line of standard therapy Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment) Other solid tumours: must have failed at least 1 line of standard therapy	NCCS-2018-Phase2-PRL3 An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours	Dr Matthew Ng	NCT04118114	Open
6	SOLID TUMORS	Any solid tumors with peritoneal mets	Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases	Dr Claramae Chia	NCT04956068	Open
7	SOLID TUMORS	ADVANCED/ METASTATIC - 2nd Line	STCC-01 A phase II multi-centre study evaluating the efficacy of dacomitinib for patients with epidermal growth factor receptor (EGFR)-driven advanced solid tumours with low EGFR-AS1 lncRNA expression or other novel emerging biomarkers	Dr Daniel Tan	NCT04946968	Open

Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1

Current clinical trials by body parts

General

Sign up today!